Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease non-alcoholic fatty liver disease
Comorbidity |diabetes
Sentences 88
PubMedID- 20460908 non-alcoholic fatty liver disease (nafld) is commonly associated with obesity and diabetes, and is characterized by insulin resistance (ir).
PubMedID- 24071688 Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin.
PubMedID- 24843757 The prevalence of nafld in patients with type 2 diabetes was 63.3%.
PubMedID- 25099524 Purpose: the relationship between chronic kidney disease (ckd) and non-alcoholic fatty liver disease (nafld) in population with diabetes remains controversial.
PubMedID- 23304532 Since nafld is closely associated with obesity, diabetes, and mets, it is unknown whether the relationship between nafld and all-cause mortality and cardiovascular death, if any, is independent of cardiometabolic risk factors (figure 1) such as mets and type 2 diabetes.
PubMedID- 25140521 Context: both longer habitual day napping and non-alcoholic fatty liver disease (nafld) are associated with diabetes and inflammation, but the association between day napping and nafld remains unexplored.
PubMedID- 21478462 Further research is required to ascertain whether the risk of progression of nafld to cirrhosis in patients with type 2 diabetes in the clinical setting is as high as that predicted—if so, this would provide further impetus toward early diagnosis so that they might be eligible for entry into clinical trials, screening for complications, and ultimately new therapies.
PubMedID- 25625278 In a recent randomized double-blind placebo-controlled phase 2 clinical trial, obeticholic acid, a semisynthetic fxr agonist derived from the primary human bile acid chenodeoxycholic acid, significantly improved markers of liver inflammation and fibrosis in nafld patients with type 2 diabetes [24].
PubMedID- 20145609 Objectives: the significance of nonalcoholic fatty liver disease (nafld) among patients with diabetes is unknown.
PubMedID- 23869321 Quoted that “non-alcoholic fatty liver disease is associated with type 2 diabetes and the metabolic syndrome.”[1] however, in the present report,[1] the retrospective review is done.
PubMedID- 25829790 Background: insulin resistance (ir) is amalgam of pathologies like altered glucos metabolism, dyslipidemia, impaired glucose tolerance, non-alcoholic fatty liver disease, and associated with type-ii diabetes and cardiometabolic diseases.
PubMedID- 24901133 Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.
PubMedID- 22723581 Type 2 diabetes is independently associated with nonalcoholic fatty liver disease (nafld) (1,2), a clinical condition potentially evolving into end-stage liver disease (3) and now recognized as an independent cardiovascular risk factor (4).
PubMedID- 23969900 Increased body mass index and diabetes mellitus are associated with developing nafld and nash, which is a severe form of nafld.
PubMedID- 20627036 Methods: this trial involved 51 patients of type 2 diabetes mellitus with nafld (g4 group), 50 patients of type 2 diabetes alone (g3 group), 45 patients of nafld alone (g2 group) and 42 healthy control subjects (g1 group).
PubMedID- 23760677 Aims/hypothesis: we have previously reported a high prevalence of non-alcoholic fatty liver disease (nafld) among women with previous gestational diabetes mellitus (pgdm).
PubMedID- 24459637 Therefore, metformin was anticipated to be beneficial in treating nash.159,160 the drug showed efficacy in patients with nafld associated with diabetes, and it improved insulin resistance and normalized alt in patients without diabetes in early studies.130,161,162 however, the drug was almost ineffective in improving findings in liver tissues.130,162 metformin has the effect of weight loss, and its combination with tzds, which have the effect of weight gain, has been reported to offset the shortcomings of tzds.
PubMedID- 22201932 Non alcoholic fatty liver disease (nafld) is associated with obesity, diabetes and insulin resistance (ir).
PubMedID- 24489859 These findings suggest that induction of autophagy by egcg may reduce hepatosteatosis found in non-alcoholic fatty liver associated with obesity and diabetes, and may play an important role in reducing high fat diet-induced hepatosteatosis.
PubMedID- 25995986 This study was conducted to evaluate changes in serum ag levels, its diagnostic accuracy and association with nafld in patients with type two diabetes (t2d).
PubMedID- 24062606 There is a very high prevalence of nafld in individuals with type 2 diabetes mellitus.
PubMedID- 26174761 The aim of this study was to determine the prevalence of nafld among individuals with type 2 diabetes in sudan.
PubMedID- 21704120 Type 2 diabetes is frequently associated with non-alcoholic fatty liver disease (nafld) which is characterized by hepatic fat accumulation and insulin resistance.
PubMedID- 20805868 [17], [18] in addition that nafld is frequently associated with type 2 diabetes, obesity and the metabolic syndrome higher serum dpp-4 activities were reported in chronic liver diseases with other origin.
PubMedID- 24595017 Since there is a close association of obesity, insulin resistance, and type 2 diabetes with nafld, we assessed whether combination of diabetes risk factors, evaluated as findrisc, was associated with hepatic steatosis in a large sample of chinese adults.
PubMedID- 20604719 Background and aims: non-alcoholic fatty liver disease (nafld) is strongly associated with obesity and diabetes mellitus.
PubMedID- 24152749 Prevalence of nafld among individuals with type 2 diabetes is estimated to be 65%–70%, which is more than twice the prevalence among people without diabetes [4,5].
PubMedID- 22024083 Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus.
PubMedID- 20217240 We used high-glucose diet to feed c57bl/6j mice for 4 weeks, measured the redox status, physiological and biochemical changes related to diabetes and consequence of metabolic syndrome (nonalcoholic fatty liver, cardiovascular disease), and detected the expressions of 14,446 genes in liver of c57bl/6j mice with dna microarray.
PubMedID- 22923470 However, it is largely unknown whether nonalcoholic fatty liver disease (nafld), a condition associated with both diabetes and fetuin-a levels (19,20), may explain or modify the association between fetuin-a and diabetes risk.
PubMedID- 25540973 In nafld patients with overweight/obesity, diabetes was the only independent predictor of nonalcoholic steatohepatitis (nash).
PubMedID- 26528424 Moreover, diabetes comorbid with nafld is associated with more severe hepatic inflammation, fibrosis and increased overall mortality compared to patients without nafld (hazard ratio [hr] 2.2, 95% ci 1.1–4.2) [22].
PubMedID- 22969728 As nafld is highly associated with obesity and diabetes, weight loss can greatly improve the health status of these patients.
PubMedID- 25844093 In contrast, another study showed no significant association between nafld and cacs in patients with diabetes [14].
PubMedID- 25951129 nafld is linked with obesity, type-2 diabetes and metabolic syndrome, and is now the most prevalent liver disorder in western countries.
PubMedID- 26201786 nafld was strongly associated with diabetes mellitus, glucose intolerance, body mass index >/=23, low high-density lipoprotein cholesterol, hypertriglyceridemia, and hypertension.
PubMedID- 24284392 The presence of nafld in individuals with type 2 diabetes appears to be a risk factor for increased mortality, with the most common causes of death being malignancy and liver disease [12].
PubMedID- 24336007 We also noted that nafld patients with type 2 diabetes are older than those without fatty liver.

Page: 1 2